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Abstract
Cholangiocarcinoma is a malignant disease of the biliary ductal system which
consists of intrahepatic (periphery) 5–10% and extrahepatic, which is further
divided into proximal (perihilar) 60–70% and distal 20–30%. The etiology of this
grave disease is unknown although many causative factors, including infectious,
congenital, and genetic factors, causing chronic inflammation, which results in
dysplastic changes of the biliary epithelium and eventual malignancy, have been
implicated. The prognosis is poor except when discovered early. The treatment of
intrahepatic (CCA) is partial hepatectomy, while radical bile duct resection with or
without hepatectomy or pancreaticoduodenectomy is considered for extrahepatic
cancer. Liver transplantation is considered in advanced diseases, without extrahe-
patic lymph node involvement. Palliation including endoscopic drainage or surgical
bypass which is an option for unresectable diseases. Adjuvant therapy in the form of
chemotherapy, immunotherapy, and photodynamic therapy is a consideration in
patients with advanced disease. Many advances have been made in the treatment of
cholangiocarcinoma, and hopefully long-term survival may be improved.
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1. Introduction
This grave illness was first described in 1840 by Durand-Fardel, as a malignant
neoplasia arising from the epithelial cells of the extrahepatic and intrahepatic bile
ducts, excluding the papilla of Vater and gallbladder. In 1965, Gerald Klatskin, a
Yale University pathologist, described the adenocarcinoma of porta hepatis. Ade-
nocarcinoma of the bile duct epithelium or cholangiocarcinoma within the conflu-
ence of the right and left hepatic duct has since then been known as “Klatskin
tumor.” The majority of this disease arises at the hepatic duct bifurcation. Surgical
resection offers the only chance for cure of this disease. Unfortunately, many
patients present with advanced locoregional and distant metastasis at the time of
diagnosis, making palliative procedures aimed at biliary drainage with intent to
prevent progressive liver failure and cholangitis, which is the only option for
unresectable tumors [1–4].
Cholangiocarcinoma (CC) is classified into proximal, perihilar or Klatskin’s
(60–70%), distal (20–30%), and intrahepatic or periphery (5–10%). They all have
different pathophysiological, epidemiological, and clinical presentations. The most
important modality of treatment for hilar cholangiocarcinoma is radical bile duct
resection with partial hepatectomy and maintenance of bilioenteric continuity. For
intrahepatic cholangiocarcinoma, partial hepatectomy is the treatment of choice,
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whereas distal cholangiocarcinoma may require pancreaticoduodenectomy. Surgical
outcome after resection for distal cholangiocarcinoma is superior to the rest. Some
subset of highly selected patients with unresectable hilar cholangiocarcinoma
(HCCA) or intrahepatic cholangiocarcinoma (ICCA) orthotopic liver transplanta-
tion (OLT) may be a viable option and has been reported to provide survival
benefits [5, 6].
2. Incidence
Statistics of autopsy report shows that the incidence of bile duct carcinoma is
0.01–0.5%. In the United States, it is 1–100,000 per year, with 3000 new cases
diagnosed yearly. Worldwide incidence is 0.5–2.0/100,000. Complete resection of
early stage tumors can be curative. When the disease is unresectable, prognosis is
generally poor with 1-year survival of 53% and 5-year survival of less than 5%. Bile
duct cancer is rare in Western countries, resulting in less than 2% in all human
cancers. It varies widely in different parts of the world. For example, in Thailand
the incidence is 113/100,000 in men and 50/100,000 in women, whereas in France
it is 1.7 and 0.5 per 100,000. In Australia, the incidence is low 0.2/100,000 in men
and 0.1/100,000 in women. In the United States, studies have shown a decline from
0.85 per 100,000 in 1995 to 0.58 per 100,000 in 2005. The frequency of bile duct
cancer increases with age, the majority of these patients are above 65 years old, with
peak incidence at seventh decade of life. Cholangiocarcinoma rarely occurs before
the age of 40 except in patients with congenital bile duct cysts. The incidence is
higher in men than women with a ratio of 1:(1.2–1.5). In the past three decades,
most studies have shown a worldwide increase in the mortality from intrahepatic
cholangiocarcinoma, whereas there is a decrease in mortality for extrahepatic and
gallbladder cancer [7–9].
3. Causative factors
The etiology of cholangiocarcinoma is unknown; however, several risk factors
proven and unproven have been attributed as a causative factor for this grave
illness. The cause of cholangiocarcinoma is associated with chronic biliary inflam-
mation; malignant transformation may occur in the background of chronic inflam-
mation and cholestasis. The production of some cytokines and reactive oxygen
species may cause permanent damage to the DNA.
4. Risk factors
The established risk factors for cholangiocarcinoma include bile duct cysts,
parasitic infection, primary sclerosing cholangitis (PSC), hepatolithiasis, and toxins.
Other potential established risk factors include inflammatory bowel disease (IBD),
hepatitis B and hepatitis C, liver cirrhosis, diabetes, obesity, alcohol, smoking, and
host genetic polymorphisms. Thorotrast, a contrast medium which is no longer in
use, although used between 1930 and 1960, was associated with several tumors
including primary liver tumor, angiosarcomas, gallbladder carcinomas, and tumors
of the extrahepatic bile duct. Several large studies from Japan, Germany, and Den-
mark showed that 45.6% of the patients exposed to Thorotrast developed liver
cancer 15–20 years after exposure, compared to 0.3% of control. This is because
biological half-life of Thorotrast is 400 years. As with other tumors, dietary
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nitrosamines are also implicated [10, 11]. Primary sclerosing cholangitis, an auto-
immune disease that results in stricturing of extra- and intrahepatic bile ducts, is an
established risk factor for CC. Chronic inflammation, proliferation of biliary epi-
thelium, production of endogenous bile mutagens, and bile stasis are postulated
mechanisms of carcinogenesis. About 70% of patients with PSC also suffer from
ulcerative colitis, but only a minority of patients with ulcerative colitis develops
PSC, so that patients with ulcerative colitis who do not have symptoms of PSC may
have increased risk of cholangiocarcinoma. It is interesting that surgical or medical
treatment of ulcerative colitis does not decrease the risk of developing cholangio-
carcinoma in patients with ulcerative colitis [12]. Hepatobiliary flukes Opisthorchis
viverrini (O. vivverini) and Clonorchis sinensis (C. sinensis) are associated with
cholangiocarcinoma irrespective of site, especially in Southeast Asia. They are
trematodes that inhabit in the bile ducts, occasionally the gallbladder, and the
pancreatic duct of mammals. Infestation of humans occurs via ingestion of raw,
pickled, or undercooked fish. Both parasites increase the susceptibility of
cholangiocytes to carcinogens causing chronic irritation and inflammation. Typhoid
organisms have been implicated in patients with cholangiocarcinoma, as well as
chronic recurrent pyogenic bacterial cholangitis [13, 14].
Hepatolithiasis are stone or gravel located in the intrahepatic biliary tree.
Hepatolithiasis is rare in the Western Hemisphere but more common in Southeast
Asia notably in Taiwan. These parasitic infestations, such as Clonorchis sinensis and
Ascaris lumbricoides, have been implicated in most patients with hepatolithiasis.
Because it is common in Asian countries, it is considered an important risk factor
for cholangiocarcinoma. The relationship between hepatolithiasis and cholangio-
carcinoma is not well established in the Western Hemisphere, except an Italian
study which showed a significant association between hepatolithiasis and ICCA
[15, 16]. Patients with congenital biliary disease have an increased risk of develop-
ing CC, compared to general population. The risk is highest in patients who did not
undergo surgical treatment, who have complete cysts excision before the age of 20,
and in those treated with cyst drainage alone, instead of complete cysts excision.
There are different types of bile duct cysts, such as extrahepatic biliary cysts and
intrahepatic biliary cysts. The etiology of cancer in patients with biliary cysts is as a
result of chronic irritation from the reflux of pancreatic enzymes, cholestasis, and
damaging effect of bile acids to biliary epithelium, resulting in the formation of
malignant cells in patients with bile duct cysts. The average age of cancer formation
is around 32, which is younger than the age of presentation of CC in the general
population. The risk of malignancy decreases in patients undergoing complete
choledochal cyst excision; surprisingly, these patients are still at an increased risk of
developing CC than the general population. Patients with an anomalous pancreati-
cobiliary ductal junction (APBDJ) have a higher incidence of developing bile duct
cancer. Ohta showed dysplastic mucosa in this group of patients [17–22].
Tocchi et al. did a retrospective review in patients with biliary-enteric drainage
for benign disease and found a high incidence of CC in this population, 5.8% in
those who underwent transduodenal sphincteroplasty, 7.6% in choledochoduo-
denostomy patients, and 1.9% in patients who had undergone hepaticoje-
junostomy [23].
Bile duct adenomas and multiple biliary papillomatosis have been shown to
have malignant transformation potential [24, 25]. Hepatitis C (HCV), hepatitis B
(HBV), and liver cirrhosis, regardless of etiology, have been shown as a risk factor
for ICCA [26].
There is an association between hepatitis C and cholangiocarcinoma in the
United States as reported in Japan. This association is not well studied, but cirrhosis
is implicated here [27]. Some studies from theWestern countries, such as Denmark,
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examined a large population of patients with liver cirrhosis over a mean follow-up
period of 6 years and showed an increase risk of cholangiocarcinoma in patients
with cirrhosis than general population. An Italian study also demonstrated an asso-
ciation between HCV and ICCA [16, 28]. As mentioned above, the Japanese study
showed an association between hepatitis C and cholangiocarcinoma. This is not
represented in the study from Korea and Thailand, where the association of hepati-
tis B and cholangiocarcinoma was shown because of the endemicity of hepatitis B in
both countries [26].
The association between diabetes, heavy alcohol drinking, smoking, and
cholangiocarcinoma is not well established. Although some studies have shown a
relationship between heavy alcohol drinking and cholangiocarcinoma, the risk fac-
tor may still be related to the presence of cirrhosis as a result of heavy alcohol
drinking [16, 29, 30].
4.1 Genetic implications
Genetic studies showed that polymorphism in genes, which codes for enzymes
implicated in the metabolism of carcinogens, DNA repair, and inflammation, can be
either pro-carcinogenic or anticarcinogenic. Mutations in oncogenes such as tumor-
suppressing genes, p53, APC, and Bcl-2, have been found in biliary duct tumors,
which include amplification and overexpression of c-erbB-2 seen in cancers of the
biliary tract. Mutations in K-ras, c-myc, c-neu, c-erbB-2, and c-met oncogenes have
also been implicated, although mutations of RAS and TP53 genes are the most
common abnormalities identified. Studies have shown that intrahepatic cholangio-
carcinoma expresses CK7, CK19, and BerEP4 with cytoplasmic staining for CEA,
unlike hepatocellular carcinoma. HER2/neu overexpression and high Ki-67 prolif-
eration index are seen frequently in patients with nodal metastasis, as well as
patients with reduced immunoexpression of E-cadherin. The suppressor p53 pro-
tein is involved in transcription, DNA repair, cell cycling, and genomic integrity.
Three types of mechanisms of p16 inactivation have been reported in biliary neo-
plasms: deletion and point mutations of the p16INK4A gene and hypermethylation
of 50 regulatory regions of p16INK4A. It appears that the vascular endothelium
growth factor expression is more in patients with extrahepatic cholangiocarcinoma
[31–37].
4.2 Clinical presentation
Patients with hilar CC present with progressive obstructive jaundice earlier
because of the location of the bile duct confluence; jaundice occurs even when the
tumor is comparably small. Symptoms include malaise, weight loss, anorexia, nau-
sea, vomiting, pruritus, and right upper quadrant pain. In patients with hilar CC,
intrahepatic bile ducts are dilated, the gallbladder is usually not palpable, and the
common duct is often collapsed on cholangiogram or ultrasound. In contrast,
patients with carcinoma in the distal common bile duct or cystic duct present
usually with a distended gallbladder and significant dilatation of the proximal bile
duct system.
The symptoms are often obscure and many times ignored, making it difficult for
early detection. As the tumor grows and obstructs the common hepatic duct and
biliary confluence, jaundice gradually develops. Most patients with hilar cholangio-
carcinoma seek medical advice because of progressive painless jaundice, accompa-
nied with pruritus with multiple skin excoriations, clay-colored stool, and dark
urine. Only patients with acute cholangitis present with fever, and this is seen only
in 10% of the cases. On physical examination the liver is enlarged and firm. The
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gallbladder is usually impalpable, except in cases of distal biliary obstruction unlike
hepatic biliary confluence obstructionwhere the gallbladder is not palpable [38, 39, 97].
4.3 Differential diagnosis
Biliary tumors are accompanied with painless jaundice which is suggestive of
biliary obstruction. Although in the clinical findings, laboratory values such as
tumor markers are non-specific and cannot specifically identify the exact cause of
the stricture, differentiating extrahepatic biliary tumor from other causes of
obstructive jaundice is important since the treatment is different.
4.4 Benign and malignant lesions masquerading as cholangiocarcinoma
Because of the close anatomic relationship of the biliary confluence to the gall-
bladder, carcinoma of the gallbladder may in some cases involve the hepatic hilum.
Systemic dissemination of malignant melanoma can involve the biliary tract mim-
icking bile duct tumor. Neuroendocrine tumors can also involve the biliary tree.
Lymph node metastatic cancers of the GI tract can also invade the bile duct as well
as primary hematolymphoidmalignancieswhich can affect the hepatic hilum [40–56].
Other legions include primary sclerosing cholangitis, secondary sclerosing cholangitis
syndromes (portal biliopathy and AIDS cholangiopathy), inflammatory pseudotumor
(autoimmune pancreatocholangitis), recurrent pyogenic cholangitis, Mirizzi syn-
drome (Type I–IV), biliary adenomas, hepatobiliary sarcoidosis, xanthogranu-
lomatous cholecystitis and cholangitis, chemotherapy-induced sclerosing cholangitis
[40–56].
5. Pathology
5.1 Gross appearance
Macroscopic appearance of CC of the extrahepatic bile ducts can be grouped into
three types, sclerosing/scirrhous, nodular, or papillary. Sclerosing/scirrhous tumors
are the most common. They may also be a combination “nodular sclerosing.” Pap-
illary variant accounts for 10% of all CC, most commonly seen in the distal bile duct
but may also be present in hilus [57].
5.2 Pre-malignant lesions
Biliary adenoma: Although these are benign tumors, a small proportion may
progress to carcinoma. Papillomatosis: Because of its multicentricity, it has a greater
malignant potential and, whenever it is encountered, complete excision. Although
difficult it is highly recommended.
Biliary cyst adenoma: Dysplastic changes leading to malignant transformation
can occur with cysto-adenocarcinoma [24, 25].
5.3 Variants
Adenocarcinoma is the most common accounting for 90%, about two-third of all
such tumors; it shows some focal intestinal differentiation with goblet and neuroen-
docrine cells. Variants include intestinal type, papillary adenocarcinoma, and mucin-
ous adenocarcinoma. Overall, papillary adenocarcinoma has better prognosis even
with lymph node metastasis. The mucinous adenocarcinoma produces an abundance
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of mucin secretion. Perineural and neural invasion is common. Clear cell carcinoma,
hepatic carcinoma, and signet ring carcinoma are all variants of cholangiocarcinoma.
Carcinosarcoma can be differentiated from squamous carcinoma because of the pres-
ence of spindle cell in the sarcoma variant. Some of these tumors can be keratinizing,
while others are not. Small-cell carcinomas are endocrine tumors with varying degrees
of differentiation; synaptophysin and chromogranin are necessary to confirm their
endocrine nature [57].
6. Staging
In accordance with the American Joint Committee on Cancer (AJCC), the stag-
ing of extrahepatic cholangiocarcinoma is based on the extent of the primary tumor
(T stage), extent of regional lymph node involvement (N stage), and presence of
distant metastasis (M stage) (Table 1). An alternative to staging system proposed
by Bismuth and Corlette classifies cholangiocarcinoma, based on the location of the
tumor with respect to the hilum and on the extent of ductal involvement (Figure 1).
AJCC staging is based largely on pathologic criteria and has little clinical signifi-
cance since most patients present with T3 (stage IVA) tumors based on invasion of
the liver. This neither says much about its resectability nor does it correlate with
survival. In the AJCC system, patients with involved N1 and N2 lymph nodes are
Anatomic stage/prognostic groups
Stage 0 Tis N0 M0
Stage I T1 N0 M0
Stage II T2a-b N0 M0
Stage IIIA T3 N0 M0
Stage IIIB T1-3 N1 M0
Stage IVA T4 N0-1 M0
Stage IVB AnyT N2 M0
AnyT Any N M1
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ
T1 Tumor confined to the bile duct, with extension up to the bile duct, with extension up to
the muscle layer or fibrous tissue
T2a Tumor invades beyond the wall of the bile duct to surrounding adipose tissue
T2b Tumor invades adjacent hepatic parenchyma
T3 Tumor invades unilateral branches of the portal vein or hepatic artery
T4 Tumor invades main portal vein or its branches bilaterally or the common hepatic artery or
the second-order biliary radicals bilaterally or unilateral second-order biliary radicals with
contralateral portal vein or hepatic artery involvement
Primary tumor (T)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
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inappropriately staged the same, since patients with metastatic disease to N2 lymph
nodes (celiac, periduodenal, or retroperitoneal) are not candidates for resection and
should be considered to have M1 disease. The Bismuth-Corlette system is more
clinically relevant if not too simplified, but it also correlates poorly with resectabil-
ity and survival. The Japanese Society of Biliary Surgery (Table 2) established a
separate pathological staging system. In this system, the T classification is meticu-
lously divided into categories of invasion because of its histological landmarks such
as mucosa, serosa, and subserosa and its depth of invasion to adjacent structures
such as the liver or pancreas which is classified into less than 5 mm, between 5 and
20 mm, and greater than 20 mm. Vascular invasion is distinguished between portal
and hepatic artery, with each type having three depths (adventitial, tunica medial,
and tunica intimal with stenosis or obstruction) numbered 1–3, respectively. This
Figure 1.
Original Bismuth-Corlette classification.
N1 Regional lymph node metastasis (including nodes along the cystic duct, common bile duct,
hepatic artery, and portal vein)
N2 Metastasis to periaortic, pericaval, superior mesenteric artery, and celiac artery lymph
nodes
Distant metastasis (M)
M0 No distant metastasis
M1 Distant metastasis
Table 1.
American Joint Committee on Cancer Seventh edition TNM staging for perihilar bile duct cancer. Anatomic
stage/prognostic groups
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classification is not popular outside of Japan due to its lack of complexity and
authenticity. The Bismuth-Corlette system has since then modified its classifica-
tions (Figure 2) from its original: Type I, non-obstructed primary confluence; Type
pT classification
pT Contents
pT1 m, fm, hinf0, panc0, pv0, a0
pT2 ss, hinf1, panc1, pv0, a0
pT3 se, hinf2, panc2, pv1, a1
pT4 si, hinf3, panc3, pv2, pv3, a2, a3
Lymph node grouping
Lymph node (site number) Group
Hilar and proximal Middle Distal
Infrapyloric LN (6) pN3 pN3 pN3
LN around the common hepatic artery
(8)
pN2 pN2 pN2
LN at the splenic hilum (10) pN3 pN3 pN3
LN along the splenic artery (11) pN3 pN3 pN3
LN at the hepatic hilum (12 h) pN1 pN2 pN2
LN along the hepatic artery (12a) pN1 pN2 pN2
Periportal LN (12p) pN1 pN2 pN2
Pericholedochal LN (12b) pN1 pN1 pN1
LN around the cystic duct (12c) pN1 pN1 pN1
Posterior superior
pancreaticoduodenal LN (13a)
pN2 pN2 pN2
Posterior inferior pancreaticoduodenal
LN (13b)
pN3 pN3 pN3
LN along the superior mesenteric
artery (14)
pN3 pN3 pN2
Para-aortic LN (16) pN3 pN3 pN3
Anterior superior pancreaticoduodenal
LN (17a)
pN3 pN3 pN3
Anterior inferior pancreaticoduodenal
LN (17b)
pN3 pN3 pN3
Stage grouping H() and P() and
M()
H(+) and/or
P(+)
and/or
pN0 pN1 pN2 pN3 M(+) and any
N
pT1 I II III IVa IVb
pT2 II III III IVa IVb
pT3 III III IVa IVb IVb
pT4 IVa IVa IVb IVb IVb
Table 2.
Japanese Society of Biliary Surgery classification for cholangiocarcinoma.
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II, obstruction limited to primary confluence; Type III, primary confluence with
extension to the right or left secondary confluence; and Type IV, extension involv-
ing bilateral biliary ductal systems.
6.1 Bismuth-Corlette classification
None of the current staging systems takes into account local factors such as
vascular invasion and hepatic lobar atrophy, which are important determinants for
resectability and surgical outcome.
The TNM system can only be determined postoperatively and on final patho-
logical specimen. A modified preoperative T staging was proposed by Jarnagin/
Blumgart (Table 3). In this staging, the nodal and distal metastases are not consid-
ered. Going from T1 to T3, the nodal and distal metastasis increases. In their series,
resectability was 59% with T1 and 0% with T3. Negative resection margin, con-
comitant hepatic resection, and well-differentiated tumor are independent predic-
tors of long-term survival. With the Jarnigan/Blumgart system, a more in-depth
framework was utilized to base preoperative decisions by predicting not only
resectability but also the likelihood of R0 resection and subsequent survival.
Stage Criteria
T1 Tumor involving biliary confluence  unilateral extension to second-order biliary radicles
T2 Tumor involving biliary confluence  unilateral extension to second-order biliary and
ipsilateral portal vein involvement  ipsilateral hepatic atrophy
T3 Tumor involving biliary confluence  bilateral extension to second-order biliary radicles or
unilateral extension to second-order biliary radicles with contralateral portal vein involvement
or unilateral extension to second-order biliary radicles with contralateral hepatic lobar atrophy
or main or bilateral portal venous involvement
Table 3.
Blumgart preoperative T staging system
Figure 2.
Modified Bismuth-Corlette classification. Type I, tumor entirely below the confluence; Type II, tumors affecting the
confluence; Type III, tumors occluding the confluence extending to the first-order right (IIIa) or left (IIIb)
intrahepatic ducts; Type IV, involving both hepatic ducts or are multicentric.
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7. Investigation and diagnosis
7.1 Evaluation of liver functional status
Liver function test and Child-Pugh score (MELD score).
Radiological: computer tomography volumetric analysis, hepatic steatosis mea-
surement.
Some centers have taken into consideration the bioenergetics which includes the
redox state of hepatocyte mitochondrial by quantifying the amount of ketone bod-
ies in the serum of the patient, as well as the measurement of cellular energy
charge through the measurement of AMP, ADP, ATP which can correlate with the
phosphorylation ability of the hepatocytes. An abnormal functioning hepatocyte
will have an alteration in energy level. Another emmerging technique is the mag-
netic resonance spectroscopy which is an in vivo non-invasive measurement of
intracellular metabolism in relationship to phosphorylation. Other tests, such as
dynamic studies (clearance tests, e.g., indocyanine green, aminopyrine,
MEGX, hexose sugar handling capacity, hepatic scintigraphy, and portal vein
embolization) [58].
7.2 Role of tumor markers
There seems to be no specific screening for Cholangiocarcinoma that is effective
accept the laboratory values which may indicate obstructive cholestasis with
hyper bilirubinemia and elevated alkaline phosphatase. The levels of CA 19-19,
CEA, and CA-125 may be elevated, but only CA 19-9 is sensitive and specific 79%
and 98% at the cut off value of 129 units/ml. Tumor markers are helpful when used
together with other diagnostic tests. CA 19-9, CEA, and CA-125, may be elevated
in patients with cholangiocarcinoma. CA 19-9 is less sensitive in patients with PSC,
53% at a cut off of greater than 100 units/L and usually would be undetectable in
some patients lacking blood type Lewis antigen who usually do not produce CA
19-9. Patients lacking blood-type Lewis antigen (10%) do not produce CA 19-9.
CA 19-9 are non-specific because they are also elevated in other gastrointestinal
tumors. CEA alone has a low sensitivity and specificity for the diagnosis of
cholangiocarcinoma. Siquiera and his associates demonstrated in their study that
CEA > 5.2 ng/mL in combination with CA 19-9 > 180 U/ml had a sensitivity of
100% and a specificity of 78.4% for the detection of cholangiocarcinoma in patients
with PSC.
However, Patel et al. compared the levels of CA 19-9 in 36 patients with cholangio-
carcinoma without PSC. They found a cutoff value of CA 19-9 > 100 units/ml with a
sensitivity of 53% for the diagnosis of cholangiocarcinoma and a true negative rate of
76% for nonmalignant liver diseases and 92% for benign biliary stricture. All the
studies show, in patients with PSC, CA 19-9 has a cutoff value of >100 U/ml and
a sensitivity of 75–89%while a specificity of 80–86% for the detection of
cholangiocarcinoma. Newer markers, such as the human mucin subtypes A and C
(mucin-5 AC), trypsinogen, and soluble fragment of cytokeratin 19, are currently
being investigated, although Bamrungphon et al. reported that mucin-5 AC at a cutoff
value of 0.074 had a sensitivity of 71% and a specificity of 90% for the diagnosis of CC.
In another study of tumor stage resectability, CA 19-9 and CEA levels increased
significantly with rising tumor stages. Patients with preoperative serum levels of CA
19-9 (> 1000 U/ml) and CEA (>14.4 ng/ml) showed a significant poorer resectability
rate [59, 60].
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8. Imaging
The most commonly used imaging modalities are ultrasound, CT scan, MRI/
MRCP, direct cholangiogram, and PET scan.
Ultrasound usually shows dilatation of the biliary tree either intra- or extrahe-
patic biliary tree. Distal obstruction is associated with both extra- and intrahepatic
dilatation, whereas proximal obstruction is associated with intrahepatic dilatation.
It can show the extent of the tumor involvement as well as encroachment to the
portal vein. Contrast-enhanced ultrasound is currently being used in the diagnosis
of hilar cholangiocarcinoma. Endoscopic ultrasound is valuable in assessing patients
with cholangiocarcinoma and its involvement with neighboring structures, espe-
cially the middle and distal part of the bile duct, but it cannot distinguish between
benign and malignant lesions [61, 62]. CT scan with intravenous contrast scanning
plays an important role in the diagnosis and staging of hilar cholangiocarcinoma,
since it can provide information regarding the location of biliary obstruction, tumor
extension, vascular invasion, hepatic lobar atrophy, lymph node involvement, dis-
tant metastases, and encroachment of the portal vein. It is even more accurate when
high-resolution multidetector-row CT scanners are used [63]. The combination of
MRI with MRCP is another effective imaging modality for staging of hilar
cholangiocarcinoma. Like CT scanning, MRI provides reliable information regard-
ing the level of biliary obstruction, vascular invasion, hepatic lobar atrophy, lymph
node involvement, as well as distant metastases. Unlike PTC, MRCP is not invasive.
It has an accuracy of 72–83% [64, 65]. ERCP and PTC involve injection of contrast
into the biliary tree. They are commonly used in the preoperative diagnosis. It is
unreliable in patients with complete bile duct obstruction. It seems to be a simple
procedure but could be met with some complications, which include bile leakage,
cholangitis, bleeding, pancreatitis, and duodenal perforation. Mortality rate ranges
between 0.6 and 5.6%. Because of its limitation it has been replaced with MRCP
[64]. FDG-PET is not superior to conventional triple-phase CT scanning in the
detection of primary lesion of hilar cholangiocarcinoma. However, it is more accu-
rate than conventional CT scan in detecting distant metastases with a sensitivity
between 56 and 100% and a specificity of 88% [66].
9. Tissue analysis
Endoscopic-guided fine-needle aspiration is useful when the results of brush
cytology and forceps biopsy are inconclusive; EUS-guided FNA can be done. Its
negative predictive value is 29%, which means that a negative EUS-guided FNA
does not necessarily exclude the possibility of hilar CC [62].
Although the diagnosis of hilar cholangiocarcinoma is primarily based on imag-
ing, it has its limitation because of its inability to differentiate between benign and
malignant strictures. Brush cytology and forceps biopsy via ERCP or PTC are the
most frequently used modality for pathological diagnosis. With brush cytology most
of the time the tissue obtained may not be sufficient to make a good pathological
assessment because the tumor may be hidden within fibrous stroma allowing for a
lower sensitivity as opposed to forceps biopsy [67]. The FISH assay can identify
malignant cells by its fluorescent probes as well as detecting abnormal chromo-
somes in the biliary cells obtained by brush cytology. It is a very advanced tech-
nique and when complemented with DIA which identifies malignant cells by the
use of special stains that quantify nuclear DNA as well as demonstrate aneuploidy
11
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are both promising [68]. The exfoliative cells found in the bile can further be
analyzed in the contest of its DNA methylation status, thereby demonstrating
evidence of malignancy in patients with equivocal findings, such as biliary stricture.
The most well studied are P16 and APC gene [69].
10. Treatment of cholangiocarcinoma
Only surgical excision of all detectable tumors is associated with an improve-
ment in 5-year survival. However, surgery can only cure a minority of patients, with
a 20–30% 5-year survival for distal lesion and a 9–18% 5-year survival for proximal
lesions. The management of patients with CC should be a multidisciplinary
approach. Patients’ general physical condition must be assessed, including pulmo-
nary and cardiovascular function, nutritional, extent of cholestasis, and a proper
assessment of resectability as well as future liver remnant. Preoperative staging
must have been done and resectability is assessed. The following criteria would
suggest an irresectable tumor: involvement of bilateral second-order intrahepatic or
extra hepatic ducts, or multifocal tumor on cholangiography, extensive involve-
ment of the main portal vein, involvement of major vessels or ducts on the contra-
lateral side of the liver, liver atrophy, and nodal metastasis to N2 lymph nodes
(peripancreatic, periduodenal, celiac, superior mesenteric, or posterior pancreati-
coduodenal lymph nodes). Lymph node involvement and peritoneal seeding may be
difficult to detect preoperatively. In this case, laparoscopy and laparoscopic ultra-
sound offer additional benefit. Laparoscopy includes likelihood of visualizing small
metastatic tumor deposits on the surface of the liver and peritoneum, which would
otherwise go undetected. Laparoscopic staging avoids extensive preparation for
inoperable patients. Cytological analysis of peritoneal washings can be done during
laparoscopy.
11. Is there a role of preoperative optimization of the liver prior
to surgical resection?
Jaundice is usually the presenting symptom in patients with hilar cholangio-
carcinoma, even when the tumor is small. Complete tumor clearance may require
extensive liver resection to obtain long-term survival. Having said that, extensive
liver resection has a mortality rate of up to 20% and morbidity rates of up to 67%.
Parenchymal transection in a jaundice and cholestatic liver may result in increased
bleeding, biliary fistula, sepsis, and impaired liver regeneration. In attempting to
improve preoperative outcome, many centers have advocated preoperative biliary
drainage and ipsilateral portal vein embolization of the hemiliver to be resected, to
improve the future of the liver remnant. In a recent French national study, serum
bilirubin was found to be correlated with mortality, which ranged from 9 to 27%
when serum bilirubin was more than 300 units (French International Value). The
choice of the route for biliary drainage is controversial. Endoscopic approach is
often difficult in patients with complete obstruction, especially when the left duct
requires drainage. Percutaneous transbiliary drainage can be done either unilateral
or bilateral. But most centers prefer a unilateral PTBD on the side of the future liver
remnant. It takes about 4–6 weeks prior to surgery and normalization of serum
bilirubin. Note that preoperative biliary drainage resulted in an increase of postop-
erative infectious complication rates [70, 71]. Although there is no randomized
study to show the benefit of portal vein embolization in hilar cholangiocarcinoma,
some people argue in favor of PVE, especially when extended right lobe resection
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and vascular reconstruction are anticipated since resection of more than 60% of the
total liver volume may result in postoperative liver failure [72].
12. Surgical treatment
It is important to determine whether an R0 resection is achievable. Is the future
liver remnant sufficient for patient survival? Is there distant metastasis and involve-
ment of level 3 lymph nodes, celiac, SMA, and aortocaval, which precludes curative
resection [73, 74]? In the last 20 years, extended liver and bile duct resection has
become the standard of care for hilar cholangiocarcinoma. In general, a remnant
liver consistent of 20–30% of the total liver mass is sufficient to prevent liver failure
following resection as long as this remaining portion is not compromised. To
accomplish this, it might be necessary to employ volumetric studies performed by
radiologists of the total and future remnant liver. Some centers advocate the use of
(ICG) 15-min retention rate and ICG clearance (K-value).
Peritoneal carcinomatosis and small intrahepatic metastasis are often not
detectable by conventional preoperative investigations. This has motivated the use
of staging laparoscopy and an analysis of peritoneal washing for patients with
HCCA [75].
12.1 Is there a role of local resection in biliary cholangiocarcinoma?
Local resection is not an adequate curative operation for HCCA, except perhaps
for small papillary Klatskin tumor without bile duct confluence involvement (Type
I Bismuth-Corlette classification, TIs and T1 AJCC staging) [76].
The goal of the surgical principle in the management of HCCA is to accomplish a
RO resection, not only cancer-free proximal and distal margin but also cancer-free
margins around the hepatoduodenal ligament. Patients should undergo a thorough
surgical exploration, especially if they have no preoperative signs of metastasis or
locally unresectable disease, because despite the selectivity and specificity of ultraso-
nography, CT scan, and MRI, almost 45% of patients who are explored are found to
have peritoneal tumor seedings, lymph node involvement, liver metastasis, or
advanced disease, all of which preclude resection. These patients may benefit with
biliary bypass and cholecystectomy to prevent future occurrence of acute cholecystitis.
At laparotomy, a generous Kocher maneuver is performed to mobilize the pan-
creatic head. During this procedure, hepatoduodenal ligament, retropancreatic and
celiac arteries are also exposed. Distal bile duct is isolated and resected at its
intrapancreatic portion. Distal margin should be submitted for intraoperative
frozen section examination. If the frozen section is negative, the distal stump is
closed. If the distal margin is positive for cancer, then a concomitant pancreatico-
duodenectomy is indicated. This applies to resectable tumors. For unresectable
perihilar malignant lesions, Roux-en-Y choledocojejunostomy to either segment II
or III bile ducts or the right hepatic duct can be performed.
For curative lesions, the location and local tumor involvement determine the
extent of resection. Perihilar tumors involving the bifurcation or above the common
hepatic duct (BC Type I or II) without any vascular involvement may be a candidate
for local resection with portal lymphadenectomy, cholecystectomy, common bile
duct excision, and bilateral Roux-en-Y hepaticojejunostomy. For lesions involving
the right or left duct (Bismuth-Corlette IIIa and IIIb), right or left hepatic lobec-
tomy can be performed. Distal bile duct tumors are frequently resectable, and if
resectable they are treated with pylorus-preserving pancreatoduodenectomy,
whereas in unresectable distal bile duct tumors, Roux-en-Y hepaticojejunostomy,
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cholecystectomy, and gastrojejunostomy should be performed to prevent gastric
outlet obstruction as the tumor progresses. The principal caudate lobe duct drains
into the left hepatic duct. Tumors extending into the left hepatic duct almost always
involve the caudate duct and will usually necessitate caudate resection. Also, a
dilated caudate duct may be suggestive of tumor involvement. The lobe is involved
by HCCA in 40–98% of patients. Retrospective studies have shown a decrease in
local recurrence and improvement in 5-year survival with concomitant caudate
resection. Tsao et al. stated that combining hilar resection and partial hepatectomy
with complete caudate lobe resection can be performed safely. Others consider
removing the caudate lobe, only when the left hepatic duct is involved.
Depending on the level of ductal involvement with surrounding structures the
following procedures can be performed:
Left or right hepatectomy with caudate lobectomy is performed for tumor
involving the left or right secondary biliary duct. Resection of the caudate lobe along
with left or right hepatectomy or sectionectomy is no more controversial in our
center. We recommend mandatory caudectomy irrespective of the type of procedure
to be carried on. Extended left or right hepatectomy with caudate lobectomy can be
considered depending on the extent of biliary and parenchymal involvement. For B/
C, Type IV tumors which involve bilateral secondary biliary radicles are considered
unresectable. These patients are candidates for palliative treatment or liver trans-
plantations. In various series of Klatskin tumors, portal vein involvement has been
found in 16–22% of patients. In addition, its propensity to spread along the bile duct
and nerves, that accompany the hepatic and celiac arteries, as well as its direct spread
to lymph nodes (53%) and adjacent liver parenchyma, has made it difficult to achieve
an R0 resection with removal of the duct alone [73].
Central hepatectomy is indicated for tumors located at the confluence of the
three segments deep within the liver substance in patients with good hepatic
reserve. This involves removal of segment 4a, 4b, 5, and 8 [77, 78].
Ex situ ex vivo autotransplantation. This highly skilled bench surgery which
involves total hepatectomy under hypothermic perfusion and complex reconstruc-
tion and reimplantation should only be attempted in experienced centers on care-
fully selected patients [79]. Bilioenteric continuity is essential to restore the
continuity of bilioenteric flow. Mucosal to mucosal anastomosis is made between a
Roux-en-Y loop of jejunum.
The role of lymphadenectomy in the staging is important, but its role in treat-
ment is debatable. Although earlier studies showed its advantage, clinical evidence
of the survival benefits of lymphadenectomy during extended resection remains
low [80, 81]. Portal vein resection can be done in cases where the tumor is adherent
to the portal vein. It is evident that combined portal vein resection offers improved
survival when compared to no resection or a resection with positive margins. Portal
vein resection for HCCA in experienced hands is not debatable and can be done,
and sometimes the resected portal vein is replaced with autologous vein or interpo-
sition graft. However, hepatic artery involvement by the tumor previously was
considered contraindication to resection but recently, some centers are resecting
and reconstructing the hepatic artery for tumors involving secondary biliary
radicles and hepatic artery. Hepatic artery reconstruction is an evolving technique,
in which more studies must be done before it becomes a standard [82, 83].
12.2 Transplantation
Surgical R0 resection is clearly the definitive choice for patients with HCCA/
ICCA and should be considered in all patients who are surgical candidates
presenting with resectable tumors. Earlier studies of long-term survival outcome
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with the radical resection of early stage hilar tumor report a 5-year survival rate of
34%; the outcome for CCA with aggressive features such as tumor size more than
2 cm multifocality remains poor because of limitation of resection as treatment
modality in achieving clear margins. For ICCA, the 5-year survival rate with nega-
tive surgical margins approached 31%; there are no survivors with residual disease.
The median time for recurrence ranges from 9 to 20 months, with the most com-
mon site being the liver remnant, occurring in 38–70% of cases and metastasis to
the regional lymph node, lung, and bones. Unfortunately many HCCA and ICCA
tumors are considered unresectable because of tumor extension to the hepatic
parenchyma, major hepatic artery, and vein of both right and left hemilivers and
metastasis to regional lymph nodes. Considering these circumstances for locally
advanced HCCA/ICCA in the absence of distant metastasis, a total hepatectomy
followed with regional lymphadenectomy followed by orthotopic liver transplan-
tation offers a viable treatment option because it will address all relevant resection
margins, as well as liver disease. Liver transplantation offers the advantage of
removing all structures that may be involved by hilar cholangiocarcinoma includ-
ing portal vein, bilateral hepatic duct, atrophic liver lobes, and hepatic artery. Total
hepatectomy will permit R0 resection for locally advanced tumors which are
beyond the ordinary criteria for resection using partial hepatectomy. Unfortunately
early reports of transplantation in patients with cholangiocarcinoma were not
successful, the 5-year survival was 20–30%, and it was considered a relative con-
traindication to liver transplantation. It was not until the group from the Mayo
Clinic developed a protocol with the intent of treating a highly selected group of
patients with CC.
The inclusion criteria involves a strict selection of patients with early stage
HCCA either deemed locally unresectable or arising in the setting of underlying
PSC. Patients with HCCA were included only if there was no mass lesion below the
level of the cystic duct. The upper limit of tumor size was 3 cm. When the mass was
visible in cross-sectional imaging studies, and there must be no evidence of
intrahepatic or extrahepatic metastasis by any imaging studies, the initial protocol
excluded patients with intrahepatic CC or gallbladder cancer (Table 4). Surgical
intervention and percutaneous biopsy were avoided to minimize percutaneous
seeding; candidates must have no active infection or medical condition to preclude
neoadjuvant therapy or liver transplantation. The candidates underwent endoscopic
ultrasound-guided regional lymph node aspiration before neoadjuvant therapy. Any
patient with positive lymph node metastases are disqualified from subsequent liver
transplantation. In the Mayo Clinic protocol, patients received external beam
radiotherapy and transcatheter radiation with iridium (Ir) 192 through a wire
placed endoscopically. Systemic 5-FU is given during radiation followed by oral
capecitabine after radiation until the day of surgery. Before transplantation all
Variables Mayo Clinic UCLA
Hilar CC Yes Yes
Hilar CC size <3 cm <3 cm
Intrahepatic CC No Yes
Intrahepatic CC size — ≤8 cm
Metastasis to hepatic parenchyma Absent Present or absent
Metastasis to regional lymph node Absent Present or absent
Metastasis to distant organ Absent Absent
Table 4.
Comparison of inclusion criteria for Mayo Clinic and UCLA treatment protocol of cholangiocarcinoma.
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patients undergo a staging laparotomy, including a biopsy of at least one lymph
node along the proper hepatic artery and another along the common bile duct, as
well as any suspicious lymph node. Only those with negative lymph nodes will
proceed with transplantation. The results of transplantation showed 1- and 5-year
survival rates of 91 and 76%, respectively, and 5 year recurrence-free survival rate
of 60%. Predictors for tumor recurrence in older patients include CA 19-9 levels
over 100 units/mL on the day of transplantation, prior cholecystectomy, tumor
grade, and residual greater than 2 cm, as well as perineural invasion in explant. A
multicenter study showed a 2- and 5-year recurrence-free survival of 78 and 65%,
respectively. There is a significant morbidity associated with this, such as
cholangitis, intrahepatic abscess and sepsis, infection, and tumor necrosis from
chemoradiation. The greatest concern is vascular complication after transplanta-
tion. The overall vascular complication rate after transplantation was 41%; 21% of
patients developed hepatic arterial complications, whereas 20% experienced portal
venous complications. To avoid using irradiated native hepatic artery, an infrarenal
interposition arterial graft was routinely used to reconstruct arterial inflow in all
deceased donor grafts, whereas the native hepatic artery was used in live donor
grafts. Although the Mayo Clinic protocol has resulted in excellent long-term
recurrence-free survival, proponents for expansion of OLT criteria argue that
patient inclusion guideline restricted to hilar tumors based only on size may exclude
patients with locally advanced hilar CC stage IIA, IIB, and III (AJCC). Despite
absence of metastatic disease, Hong et al. have recently reported that survival
benefits can also be achieved in patients with locally advanced CC (>3 cm in size,
tumor extension to hepatic parenchyma, branches of portal vein or hepatic artery,
presence of perineural and lymphovascular invasion). Using a neoadjuvant and
adjuvant protocol, they had a 5-year disease recurrence-free survival of 47% in
patients who received OLT in combination with neoadjuvant and adjuvant thera-
pies than 0% in the resection group [84–86].
12.3 Is there a role of adjuvant therapy in the treatment
of cholangiocarcinoma?
Some centers reported the use of intraoperative radiotherapy, Busse et al. These
results are rather conflicting with no significant difference in mean survival.
Although Kamada et al. suggested that radiotherapy may increase survival in
patients with positive hepatic duct resection margins. If this modality is to be used
postoperatively, metal clips should be placed to mark the area of the anastomosis
after resection or areas of known or suspected residual tumors. Despite significant
advances in the surgical management of perihilar cholangiocarcinoma, the only
chance for long-term survival remains complete resection with negative margins.
Radiation therapy alone has no significant impact in prolonging survival in these
patients. Some centers are using gemcitabine in combination with cisplatin along
with radiation, although anecdotal but rather promising. Both gemcitabine and
cisplatin have been demonstrated in recent years to have activity against hilar CC,
and a recent phase 3 trial suggests that the best results can be achieved with a
combination of these two agents [87–91].
12.4 Palliative therapy
Most patients with HCCA may not be suitable for surgical resection. If a patient
is considered irresectable after histological or cytological tissue is confirmed to be
cancerous, palliative measures can be an option. The palliative measures include
biliary decompression either surgical, endoscopic, or percutaneous techniques
which can be applied in unresectable tumors as well as chemotherapy, radiation
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therapy, and photodynamic therapy. Palliative biliary bypass can be performed by
exposing the left hepatic duct; this involves (1) opening the umbilical fissure,
elevating the base of the segment 4 lobe, while lowering the left hepatic ductal
system from the undersurface of the quadrate lobe, (2) exposing branches of the
left duct by dissection at the base of the ligamentum teres, (3) by partial excision of
the left lateral segment and performing a biliary-enteric anastomosis to the opening
in branches of the left hepatic duct (Longmire procedure), and (4) Cahow’s
intrahepatic cholangiojejunostomy. If the left hepatic duct is not accessible, the
right drainage system (V or VI) can be exposed by a hepatotomy at the base of the
gallbladder fossa, but in general, segment III bypass is performed, unless the left
liver is atrophic or is heavily involved with tumors or in cases of the primary lesion
extending to the umbilical fissure of the liver [92, 93].
12.5 What are the importance of endoscopic and percutaneous
methods and when is it indicated?
The use of these modalities differs from center to center. Routine biliary drain-
age is not recommended before assessing resectability, except in patients with
suppurative cholangitis or patients with severe renal dysfunction and malnutrition.
Endoscopic palliation of jaundice in patients with HCCA is best achieved in patients
in whom preoperative drainage was achieved endoscopically. At the present time,
percutaneous drainage of the biliary system is a useful tool in patients in whom
endoscopic drainage cannot be achieved due to technical difficulties and in non-
availability of advanced endoscopic facilities. Endoscopic stent insertion can also be
used to deliver other forms of palliative adjuvant therapy, such as brachytherapy
and photodynamic therapy. The development of newer stents and techniques for
deployment as well as the rapidly emerging applications of EUS could widen the
scope of endoscopy as a palliative tool in HCCA. It is technically easier to place
endoscopically or percutaneously in patients with distal lesions than proximal
lesions. The patency for metallic stents at the hilar region is less than those placed in
the distal duct. Endoscopic, percutaneous, and operative approaches to biliary
decompression are effective. The patency for distal stent is higher than the proximal
stents. It might be technically difficult to place a stent to the proximal lesion
endoscopically. In this scenario, percutaneous approach may be better for proximal
lesions. Stents can be placed unilateral or bilateral and sometimes unilateral stent
placement may be adequate. The patency of self-expanding bare metal stents is
higher than polyethylene plastic stents. Covered stents have a comparable patency
rate to bare metal stents, but they are associated with an increased rate of compli-
cation which involves stent migration. Photodynamic therapy is emerging as a
promising option for palliative therapy, while brachytherapy is still evolving. Both
approaches remain, at this time, investigational for CC palliation. It is important
that the optimal management of patients with CC requires a multidisciplinary team
of clinicians, including surgeons, interventional and diagnostic radiologists, gastro-
enterologist, and hepatologists [94, 95].
12.6 Photodynamic therapy and immunotherapy
This approach has been used as a palliative measure for tumors of the esophagus,
colon, and stomach. It is promising as a means of providing biliary decompression
without stents or another means of treating those with microscopically involved bile
duct margins. It uses two nontoxic components, a photosensitizing chemical called
photosensitizer and light which is applied in sequence. The wavelength of the photo-
sensitizer corresponds to the absorption spectra of the photosensitizer, and it is
activated by several wavelengths. To achieve tumor necrosis, it is better to use the
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photosensitizer with the longest wavelength. With oxygen molecules present, this
results in the release of various cytotoxic species, like singlet oxygen and other
reactive oxygen species. Photodynamic therapy is both anti-angiogenic which dam-
ages tumor endothelial cells as well as dose-dependent immune responses. At high
doses, it causes damage to the cellular membranes and the blood vessel which leads to
recruitment of neutrophils and monocytes/macrophages and activation of pro-
inflammatory cytokines like interleukin IL-1beta, IL-2, and tumor necrosis factor
TNF-alpha. This results in the enhancement of the host immune system which plays
an important role in secondary cytotoxicity and tumor control. Serum IL-6, a bile
duct epithelium growth factor correlating with tumor burden in CC, decreases after
PDT. The side effect of PDT is cutaneous photosensitivity [96]. Although not con-
clusive, but at its preliminary stage as discussed earlier, biliary cancers that express
epidermal growth factor and angiogenesis have been correlated with poor prognosis.
Erlotinib and EGFR tyrosine kinase inhibitor and bevacizumab, a vascular endothelial
growth factor (VEGF) inhibitor, have been shown to have activity in biliary cancer.
Inhibitors of epidermal growth factor receptor family, such as erlotinib, cetuximab,
and lapatinib, were recently investigated. Furthermore, bortezomib (an inhibitor of
proteasome), imatinib mesylate (an inhibitor of c-kit-R), bevacizumab (an inhibitor
of VEGF), and sorafenib (a multiple kinase inhibitor), that blocks not only tyrosine
kinase but also serine/threonine kinases along the RAS/RAF/MEK/ERK pathway,
have been used. Early evidence of antitumor activity was seen, but the results are still
too early and require further investigation [36].
13. Summary
Cholangiocarcinoma is a very deadly disease, which if diagnosed early and if the
patient is subjected to a complete surgical resection may have an impact in long-term
survival. Having said that, much progress has been made with multidisciplinary
services, transplantation, aggressive surgical approach, and hopefully with new
developments in technology and research; we hope to improve the survival rate.
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